ArticleOpen forum infectious diseases2026
Bridging the Gap: Measles Susceptibility and Neutralization Test-Confirmed Immunity in a Spanish HIV-PrEP Cohort.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Measles is re-emerging in highly vaccinated settings, where small gaps in adult immunity may persist. Standard IgG assays are widely used to assess measles immunity, but negative or borderline results may not reflect absence of functional protection. HIV pre-exposure prophylaxis (HIV-PrEP) programs provide regular preventive-care contact and may offer an opportunity to review adult measles immunity. We assessed measles immunity in a Spanish HIV-PrEP cohort using chemiluminescence immunoassay (ChLIA) and neutralization testing (NT). Methods: We performed a cross-sectional analysis of 155 participants enrolled in a prospective HIV-PrEP cohort in Córdoba, Spain. Measles-specific IgG was measured by ChLIA. All ChLIA-negative or borderline samples, together with 30 randomly selected ChLIA-positive samples, underwent NT. Confirmed susceptibility was defined as ChLIA-negative/borderline and NT negative. Results: Among participants, 149 (96.1%) were male and the median age was 37 years. ChLIA classified 125 participants (80.6%) as IgG-positive, 27 (17.4%) as negative, and 3 (1.9%) as borderline. Among 30 ChLIA-negative/borderline samples, 23 (76.7%) were NT positive and 7 (23.3%) NT negative. All 30 randomly selected ChLIA-positive samples were NT positive. Overall, 7 participants (4.5%) lacked confirmed measles immunity. All were Spanish-born men aged 26-39 years, and 4 had documented 2-dose measles-mumps-rubella vaccination completed at least 20 years before inclusion. Conclusions: Confirmed measles susceptibility was uncommon in this HIV-PrEP cohort. Most participants with negative or borderline ChLIA results retained neutralizing antibodies, indicating that isolated ChLIA findings may overestimate susceptibility. Routine adult preventive-care encounters may provide opportunities to review measles immunity documentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.